Company: BIAF
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001493152-25-023405
Chunk: 8

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-11-14
Form: 10-Q
Item: Part I, Item 8
Chunk 8
---
,840)

    Balance at September 30, 2024 (unaudited) 
     —  
    $—  
     433,575  
    $3,002  
    $53,795,436  
    $(50,677,413) 
    $3,121,025 
  
    Balance 
     —  
    $—  
     433,575  
    $3,002  
    $53,795,436  
    $(50,677,413) 
    $3,121,025 

(3)The
                                            values of Common Stock and paid-in capital, as well as the number of shares issued and outstanding,
                                            have been retroactively adjusted in order to give effect to the Company’s 1-for-30
                                            reverse stock split.

The
accompanying notes are an integral part of these condensed consolidated financial statements.

7

bioAffinity
Technologies, Inc.

Unaudited
Condensed Consolidated Statements of Cash Flows

(unaudited)

    2025  
    2024 

    Nine Months Ended September 30, 

    2025  
    2024 

    Cash flows from operating activities 

    Net loss 
    $(11,772,288) 
    $(6,072,934)
  
    Adjustments to reconcile net loss to net cash used in operating activities: 

    Depreciation and amortization 
     381,177  
     452,005 
  
    Stock-based compensation expense 
     605,355  
     755,594 
  
    Fair value adjustment on warrants 
     3,810,278  
     — 
  
    Changes in operating assets and liabilities: 

    Accounts and other receivables 
     690,214  
     (515,494)
  
    Inventory 
     (7,626) 
     (6,879)
  
    Prepaid expenses and other assets 
     (30,331) 
     (122,626)
  
    Accounts payable 
     (46,550) 
     178,148 
  
    Accrued expenses 
     (414,175) 
     (245,559)
  
    Unearned revenue 
     13,511  
     (8,654)
  
    Operating lease right-of-use asset